KORU Medical Systems, Inc. — Earnings Quality Grade F
KRMD · Healthcare
Major red flags
Screening Summary
Management Signals
Financial Trends
Revenue & Net Income ($B)
Margins (%)
18-Point Screening
Revenue Quality
DSO 52 days, change -7 days YoY
AR growth 7.1% vs revenue growth 22.2%
Revenue 22.2%, CFFO 244.6%. Cash follows revenue
Expense Quality
Inventory 31.2% vs COGS 26.1%. Normal
CapEx growth -28.7% vs revenue 22.2%. Normal
SG&A/Gross Profit = 91.3%, exceeds 70%
Gross margin 62.3%, change -1.1pp. Stable
Cash Flow Quality
CFFO < Net Income for 3 consecutive years
Small-cap context: Small-cap CFFO/NI often diverges from working-capital swings, not necessarily manipulation.
FCF is negative ($-0.0B)
Accruals ratio = -11.0%. Low accruals
Cash $0.0B covers debt $0.0B
Balance Sheet Health
No goodwill. Clean balance sheet
Debt/EBITDA = -1.6x. Healthy
Other assets 0.0% vs revenue 22.2%. Normal
No write-off data
Acquisition Risk
FCF after acquisitions negative for 3 years
Small-cap context: A single acquisition on a small balance sheet can trip serial-acquirer logic.
No goodwill
Manipulation Score
M-Score = -2.94 (< -2.22). Unlikely manipulator
Portfolio monitoring
Monitor KRMD continuously
The full checks and model details are free to read. Use Watchlist to track your holdings; Pro adds automatic quarterly rescoring, risk-event email alerts, scans up to 50 tickers, and export workflows.
Beneish M-Score
Altman Z-Score
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25